Epstein-Barr virus-associated lymphoepithelioma-like cholangiocarcinoma: A rare variant of intrahepatic cholangiocarcinoma with favourable outcome

Histopathology

Volumn 65, Issue 5, 2014, Pages 674-683

  Chan, Anthony W H ^a   Tong, Joanna H M ^a,b   Sung, Mandy Y M ^a   Lai, Paul B S ^b   To, Ka Fai ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cholangiocarcinoma; Epstein Barr virus; Lymphoepithelioma; Methylation

Indexed keywords

CYTOKERATIN 7; CYTOKERATIN 9; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA METHYLATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOEPITHELIOMA; LYMPHOEPITHELIOMA LIKE CHOLANGIOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; SURVIVAL RATE; TUMOR VOLUME; ADENOCARCINOMA; BILE DUCT CARCINOMA; CARCINOMA; EPSTEIN BARR VIRUS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VIROLOGY;

HUMAN HERPESVIRUS 4;

ADENOCARCINOMA; ADULT; BIOMARKERS, TUMOR; CARCINOMA; CHOLANGIOCARCINOMA; DNA METHYLATION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84906722239     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12455     Document Type: Article

References (36)

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004; 4; 757-768.
2. Adachi S, Morimoto O, Kobayashi T. Lymphoepithelioma-like cholangiocarcinoma not associated with EBV. Pathol. Int. 2008; 58; 69-74.
3. Chen TC, Ng KF, Kuo T. Intrahepatic cholangiocarcinoma with lymphoepithelioma-like component. Mod. Pathol. 2001; 14; 527-532.
4. Henderson-Jackson E, Nasir NA, Hakam A, Nasir A, Coppola D. Primary mixed lymphoepithelioma-like carcinoma and intra-hepatic cholangiocarcinoma: a case report and review of literature. Int. J. Clin. Exp. Pathol. 2010; 3; 736-741.
5. Hsu HC, Chen CC, Huang GT, Lee PH. Clonal Epstein-Barr virus associated cholangiocarcinoma with lymphoepithelioma-like component. Hum. Pathol. 1996; 27; 848-850.
6. Huang Y, Tsung JS, Lin CW, Cheng TY. Intrahepatic cholangiocarcinoma with lymphoepithelioma-like carcinoma component. Ann. Clin. Lab. Sci. 2004; 34; 476-480.
7. Hur YH, Kim HH, Koh YS, Seoung JS, Cho CK. Lymphoepithelioma-like cholangiocarcinoma not associated with Epstein-Barr virus. ANZ J. Surg. 2011; 81; 652-653.
8. Jeng YM, Chen CL, Hsu HC. Lymphoepithelioma-like cholangiocarcinoma: an Epstein-Barr virus-associated tumor. Am. J. Surg. Pathol. 2001; 25; 516-520.
9. Kim YB, Park YN, Han JY, Hong KC, Hwang TS. Biliary lymphoepithelioma-like carcinoma not associated with Epstein-Barr virus. Arch. Pathol. Lab. Med. 1999; 123; 441-443.
10. Lee W. Intrahepatic lymphoepithelioma-like cholangiocarcinoma not associated with Epstein-Barr virus: a case report. Case Rep. Oncol. 2011; 4; 68-73.
11. Ortiz MR, Garijo G, Adrados M, Lopez-Bonet E, Acero D, Bernado L. Epstein-Barr virus-associated cholangiocarcinoma with lymphoepithelioma-like component. Int. J. Surg. Pathol. 2000; 8; 347-351.
12. Szekely E. Lymphoepithelioma-like cholangiocarcinoma (LELC) not associated with Epstein-Barr virus. Am. J. Surg. Pathol. 2001; 25; 1464-1466.
13. Vortmeyer AO, Kingma DW, Fenton RG, Curti BD, Jaffe ES, Duray PH. Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus. Am. J. Clin. Pathol. 1998; 109; 90-95.
14. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr virus (EBV)-associated gastric carcinoma. Viruses 2012; 4; 3420-3439.
15. Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin. Cancer Biol. 2012; 22; 79-86.
16. Isomoto H. Epigenetic alterations associated with cholangiocarcinoma [Review]. Oncol. Rep. 2009; 22; 227-232.
17. Karbanova J, Missol-Kolka E, Fonseca AV et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J. Histochem. Cytochem. 2008; 56; 977-993.
18. Nakanuma Y, Curado MP, Franceshi S et al. Intrahepatic cholangiocarcinoma. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer, 2010; 217-224.
19. Fan L, He F, Liu H et al. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer 2011; 11; 320.
20. Shimada M, Sugimoto K, Iwahashi S et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J. Gastroenterol. 2010; 45; 896-902.
21. Grinstein S, Preciado MV, Gattuso P et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res. 2002; 62; 4876-4878.
22. Nemolato S, Fanni D, Naccarato AG, Ravarino A, Bevilacqua G, Faa G. Lymphoepitelioma-like hepatocellular carcinoma: a case report and a review of the literature. World J. Gastroenterol. 2008; 14; 4694-4696.
23. Kim BH, Cho NY, Choi M, Lee S, Jang JJ, Kang GH. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Arch. Pathol. Lab. Med. 2007; 131; 923-930.
24. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod. Pathol. 2005; 18; 412-420.
25. Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol. Int. 2010; 60; 337-350.
26. Kwong J, Lo KW, Chow LS et al. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 2005; 7; 67-74.
27. Tong JH, Ng DC, Chau SL et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010; 10; 253.
28. Tsai CL, Li HP, Lu YJ et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 2006; 66; 11668-11676.
29. Hino R, Uozaki H, Murakami N et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009; 69; 2766-2774.
30. Han J, Chen JN, Zhang ZG et al. Sequence variations of latent membrane protein 2A in Epstein-Barr virus-associated gastric carcinomas from Guangzhou, southern China. PLoS One 2012; 7; e34276.
31. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J. Hepatol. 2002; 37; 633-639.
32. Esteller M, Guo M, Moreno V et al. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 2002; 62; 5902-5905.
33. Caren H, Fransson S, Ejeskar K, Kogner P, Martinsson T. Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br. J. Cancer 2007; 97; 1416-1424.
34. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 2011; 31; 173-187.
35. Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010; 11; 1142-1148.
36. Lee J, Park SH, Chang HM et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012; 13; 181-188.